Occam Places Bill Brondyk as CSO at Invetx
_430x344.jpg)
Invetx, an Anterra Capital investment, is building the world’s premier biotechnology platform for protein-based therapeutics in animal health to transform standards of care in veterinary medicine. In 2020, the company raised a $15M series A to advance Invetx’s pipeline of veterinary biologic drugs leveraging breakthroughs in human biopharma. Partnerships with AbCellera and WuXi Biologics followed shortly after. And in 2022, the company closed a $60M series B from F-Prime, Novo and Casdin.
But before all that, in September of 2019, Occam recruited Bill Brondyke to be the company's first CSO. Brondyke is seasoned drug hunter with 20+ years of experience in developing protein therapeutics for oncology indications, immune-mediated diseases, infectious diseases, rare diseases and reproductive health and contraception.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.